Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1233092.RAvJasnLtA9ZspUgySvYYyXQSB9_dTPHb8eXUxMBf0YYs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1233092.RAvJasnLtA9ZspUgySvYYyXQSB9_dTPHb8eXUxMBf0YYs130_assertion type Assertion NP1233092.RAvJasnLtA9ZspUgySvYYyXQSB9_dTPHb8eXUxMBf0YYs130_head.
- NP1233092.RAvJasnLtA9ZspUgySvYYyXQSB9_dTPHb8eXUxMBf0YYs130_assertion description "[Manipulating the expression of mutant or wild-type PIK3CA or DUSP1 confirmed that this mechanism is responsible for the induction of apoptosis and the inhibition of tumour proliferation in vitro and in vivo, to sensitise cells to AKT target therapy.Conclusion or interpretation:PIK3CA mutations confer sensitivity to AKT target therapy in BLCA by regulating DUSP1 expression and subsequent ERK1/2 dephosphorylation and can potentially serve as a stratifying biomarker for treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233092.RAvJasnLtA9ZspUgySvYYyXQSB9_dTPHb8eXUxMBf0YYs130_provenance.
- NP1233092.RAvJasnLtA9ZspUgySvYYyXQSB9_dTPHb8eXUxMBf0YYs130_assertion evidence source_evidence_literature NP1233092.RAvJasnLtA9ZspUgySvYYyXQSB9_dTPHb8eXUxMBf0YYs130_provenance.
- NP1233092.RAvJasnLtA9ZspUgySvYYyXQSB9_dTPHb8eXUxMBf0YYs130_assertion SIO_000772 25349966 NP1233092.RAvJasnLtA9ZspUgySvYYyXQSB9_dTPHb8eXUxMBf0YYs130_provenance.
- NP1233092.RAvJasnLtA9ZspUgySvYYyXQSB9_dTPHb8eXUxMBf0YYs130_assertion wasDerivedFrom befree-2016 NP1233092.RAvJasnLtA9ZspUgySvYYyXQSB9_dTPHb8eXUxMBf0YYs130_provenance.
- NP1233092.RAvJasnLtA9ZspUgySvYYyXQSB9_dTPHb8eXUxMBf0YYs130_assertion wasGeneratedBy ECO_0000203 NP1233092.RAvJasnLtA9ZspUgySvYYyXQSB9_dTPHb8eXUxMBf0YYs130_provenance.